inbio_n (9)standard-scalex
Subtraction 3 Subtraction 4
Path 49
2.2 million

2.2 million women suffer from breast cancer per year worldwide.

25%/70%
1/6

Uncover the Undiscovered

Breast cancer is the most commonly diagnosed cancer for women, and still remains the leading cause of cancer death in women worldwide. Most deaths are due to metastatic spread rather than to the primary tumor.

Currently there is a growing unmet need for biomarkers for effective patient management to identify patients that will benefit an adjuvant treatment to prevent disease spread.

There is a serious impact on the outlook of the future of patients with breast cancer because, given the uncertainty of facing relapse or metastasis, today’s cure is no guarantee for tomorrow.

We want to shift the perspective and provide more personalized treatment plans driven by knowledge and based on precision medicine.

Path 6
Perspective from knowledge
inbio_home_mid
Graphic_Pin_Point_Gray

Uncovering the MAF gene biology

Adjuvant bisphosphonates are generally recommended by clinical guidelines for postmenopausal women with early breast cancer deemed at significant risk for recurrence.

We have developed the MAF Test
®, that aims to improve
patient selection for adjuvant bisphosphonate treatment of
early breast cancer patients. Using patient specimens from
two landmark trials in adjuvant breast cancer treatment
(AZURE and NSABP-B34), we uncovered the biology of the
MAF gene and its clinical utility.


Benefits from adjuvant bisphosphonates are seen in 80% of patients with normal levels of MAF gene expression, irrespective of menopausal status and age, while over expression is associated with a poor prognosis and a worse outcome linked to a higher rate of metastases.

This discovery drives a new perspective on the treatment plan in early breast cancer.

Enabling personalised adjuvant therapies with the aim to improve breast cancer patients’ risk of relapse and overall survival.

About in.bio.motion
Path 8
News
Line 1

SPA Farma and Inbiomotion sign an exclusive agreement

The exclusive agreement will make the novel MAF Test® for identifying high risk early-stage breast cancer patients available in Italy.

Path 200
Download
Path 8

1 out of 4 of women with early breast cancer may develop metastasis over their life time, with more than 7 out of 10 with bone metastasis.

Breast cancer is the leading cause of cancer death for women worldwide, accounting for 1 in 6 cancer deaths. Breast cancer claims the lives of more European women than any other cancer.

Prof. Dr. Roger Gomis, ICREA Researcher
in.bio.motion

Polygon 2

"In.bio.motion is raising the question: did previous trials miss the mark by not pre-selecting the correct women who are at-risk and who would benefit from these treatments?

Mask Group 4 Exclusion 1
80%

of woman is
MAF Negative

20%

of woman is
MAF Positive

MAF Test®

MAF Test® biomarker aims to allowing doctors to select breast cancer patients who are MAF-negative for adjuvant treatment with bisphosphonates, and excluding those who are MAF-positive from an ineffective treatment and potential harm.

MAF negative patients may be eligible for adjuvant treatment with bisphosphonates in early breast cancer, including non-post-menopausal patients currently not recommend in clinical guidelines.

MAF positive patients may be excluded from adjuvant treatment with bisphosphonates, including post-menopausal patients who do not benefit or may be harmed.

Path 64
MAF Test® Clinical Evidence
Path 8
Path 171
Perspectives
inbio_n (9)standard-scalex Subtraction 4 Subtraction 3

There is a serious impact on the outlook of the future of patients with breast cancer because, given the uncertainty of facing relapse or metastasis, today’s cure is no guarantee for tomorrow.

We want to shift the perspective and provide more personalized treatment plans driven by knowledge and based on precision medicine.

Breast cancer is the most commonly diagnosed cancer for women, and still remains the leading cause of cancer death in women worldwide. Most deaths are due to metastatic spread rather than to the primary tumor.

Currently there is a growing unmet need for biomarkers for effective patient management to identify patients that will benefit an adjuvant treatment to prevent disease spread.

Uncover the Undiscovered

Adjuvant bisphosphonates are generally recommended by clinical guidelines for postmenopausal women with early breast cancer deemed at significant risk for recurrence.

We have developed the MAF Test
®, that aims to improve patient selection for adjuvant bisphosphonate treatment of early breast cancer patients. Using patient specimens from two landmark trials in adjuvant breast cancer treatment (AZURE and NSABP-B34), we uncovered the biology of the MAF gene and its clinical utility.


Benefits from adjuvant bisphosphonates are seen in 80% of patients with normal levels of MAF gene expression, irrespective of menopausal status and age, while over expression is associated with a poor prognosis and a worse outcome linked to a higher rate of metastases.

This discovery drives a new perspective on the treatment plan in early breast cancer.

Enabling personalised adjuvant therapies with the aim to improve breast cancer patients’ risk of relapse and overall survival.

About in.bio.motion
Path 8

Uncovering the MAF gene biology

inbio_home_mid
Path 49

2.2 million

2.2 million women suffer from breast cancer per year worldwide.

25%/70%

1 out of 4 of women with early breast cancer may develop metastasis over their life time, with more than 7 out of 10 with bone metastasis.

1/6

Breast cancer is the leading cause of cancer death for women worldwide, accounting for 1 in 6 cancer deaths. Breast cancer claims the lives of more European women than any other cancer.

News
Line 1

SPA Farma and Inbiomotion sign an exclusive agreement

The exclusive agreement will make the novel MAF Test® for identifying high risk early-stage breast cancer patients available in Italy.

Path 200
Download
Path 8
Path 6
Perspective from knowledge

Prof. Dr. Roger Gomis, ICREA Researcher
in.bio.motion

"In.bio.motion is raising the question: did previous trials miss the mark by not pre-selecting the correct women who are at-risk and who would benefit from these treatments?

20%

of woman is
MAF Positive

80%

of woman is
MAF Negative

MAF Test® biomarker aims to allowing doctors to select breast cancer patients who are MAF-negative for adjuvant treatment with bisphosphonates, and excluding those who are MAF-positive from an ineffective treatment and potential harm.

MAF negative patients may be eligible for adjuvant treatment with bisphosphonates in early breast cancer, including non-post-menopausal patients currently not recommend in clinical guidelines.

MAF positive patients may be excluded from adjuvant treatment with bisphosphonates, including post-menopausal patients who do not benefit or may be harmed.

Path 64
MAF Test® Clinical Evidence
Path 8
MAF Test®
Path 171
Perspectives
Path 107 inbio_n (8)

With more accurate information, oncologists can provide patients the knowledge to explore treatment plans with better prognoses to avoid relapse, allowing them to live with greater clarity.

PATIENTS PERSPECTIVE
Path 8
For
Patients
Path 76
new_MJ-images (9)
For Oncologists
Path 77

With this new insight, oncologists will gain a valuable tool to add to their arsenal, having the power to make a difference in the lives of their patients.

Path 64
ONCOLOGIST PERSPECTIVE
Path 8
new_MJ-images (6)
For Pathologists
Path 78

With the MAF Test®, pathologists can provide better insights to support informed decisions. Contributing to help delivering optimal treatments that fit each patient's unique needs.

Path 64
PATHOLOGIST PERSPECTIVE
Path 8
Path 75

Together, we will drive
new perspectives
towards a future where
breast cancer is no
longer a life-threatening
disease.